SciELO - Scientific Electronic Library Online

 
vol.86 issue5Case for diagnosisDo you know this syndrome? author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Anais Brasileiros de Dermatologia

Print version ISSN 0365-0596

An. Bras. Dermatol. vol.86 no.5 Rio de Janeiro Sept./Oct. 2011

http://dx.doi.org/10.1590/S0365-05962011000500032 

DO YOU KNOW THIS SYNDROME?

 

Do you know this syndrome?*

 

 

Giovana Tadéia FantinatoI; Silmara da Costa Pereira CestariII; João Paulo Junqueira Magalhães AfonsoIII; Letícia Siqueira SousaIII; Mílvia Maria Simões e Silva EnokiharaIV

IDermatologist (MD) and pediatric dermatology specialist trainee at the Department of Dermatology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
IIAssociate Professor responsible for the Pediatric Dermatology Clinic of the Department of Dermatology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil
IIIMD - Resident in the Department of Dermatology, Federal University of São Paulo (UNIFESP, São Paulo, Brazil
IVPhD in Pathology, physician in the Department of Pathology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil

Mailing address

 

 


ABSTRACT

Chediak-Higashi syndrome is characterized by varying degrees of oculocutaneous albinism, recurrent infections, bleeding disorders and variable neurological involvement. The treatment consists of bone marrow transplantation, which corrects the immunologic and hematologic defects. Untreated patients die as the result of bacterial infections or develop "accelerated phase" lymphoproliferation. We present a case of Chediak-Higashi syndrome and discuss the clinical and laboratorial features that determine its diagnosis.

Keywords: Chediak-Higashi Syndrome; Diagnosis; Hypopigmentation; Lysosomes


 

 

RELATO DO CASO

Male patient, native of São Paulo, normal birth at full term, with healthy parents and first cousins. First dermatologic assessment at 3 months of age revealed silver hair color, white eyebrows and eyelashes and skin hypopigmentation, all features not shared with his parents. (Figure 1). An optical microscopy examination of the patient´s hair showed groups of pigment scattered along the length of the hair shafts, contrasting with the normal pattern of fine, diffuse pigmentation (Figure 2). Opthalmic fundus examination revealed foveal hypoplasia and albinism, while analysis of otoacoustic emissions showed delayed auditory development of bilateral retrocochlear origin. A peripheral blood smear showed the presence of giant intracytoplasmic granules in leukocytes (Figure 3). The patient was hospitalized for H1N1 virus infection and febrile neutropenia and then treated as an outpatient for impetigo and ear infections. The child, now aged 18 months, has normal psychomotor development and is being tracked by the dermatology, genetics and immunology departments while awaiting a bone marrow transplant.

 

 

 

 

 

 

DISCUSSION

Chediak-Higashi syndrome (CHS) is a rare autosomal recessive disorder characterized by oculocutaneous albinism, immunodeficiency, progressive neurological disorders, bleeding predisposition and lymphoproliferative syndrome. While the primary defect of the CHS is unknown, the clinical symptoms are attributed to a vesicular trafficking defect secondary to enlarged granules in the lysosomes and melanosomes and platelet dense granules. Skin hypopigmentation is variable, and in some individuals is only noticeable when compared to other family members. The hair is silver-colored or has a metallic sheen. Giant melanosomes can be observed through microscopic examination of the skin. The discovery of groups of large pigment granules in the hair shaft has been used for prenatal diagnosis of CHS. 2 Reduced pigment may be observed in the eyes, and nystagmus, photophobia and decreased visual acuity can result. The iris can be grayish, bluish or brownish. 3 Patients develop recurrent infections, mainly in the skin and airways, and are responsive to antibiotic therapy, although more slowly than immunocompetent individuals. The immune defect is attributed to impaired cytolytic function of T and Natural Killer (NK) cells, and delayed neutrophil and monocyte chemotaxis. 4.5 Mild to moderate bleeding can occur. Bleeding can be severe at the accelerated phase when thrombocytopenia occurs in addition to platelet dysfunction. 6 Neurologic changes may occur in the central or peripheral nervous system, with progressive neurodegeneration. 7 Around 85% of patients progress to the accelerated phase which is characterized by multiple organ linfohistiocitary infiltration, non-malignant but similar to lymphoma and manifested by fever, anemia, neutropenia, thrombocytopenia, hepatosplenomegaly, lymphadenopathy, jaundice and coagulopathy. The diagnosis of CHS is confirmed (i) by finding giant peroxidasepositive cytoplasmic granules in polymorphonuclear cells, as well as in other cells such as leukocytes, platelets, melanocytes, hepatocytes, renal tubular cells, neural and thyroid tissue, or (ii) by genetic analysis, with mutation in the LYST/CHS1 gene on chromosome 1. 8 Death usually occurs in the patient´s first ten years of life from infection or bleeding, or later when the disease progresses to accelerated phase. 9 Curative treatment consists of bone marrow transplantation to correct the immune and hematologic defect, but oculocutaneous and neurological changes nevertheless persist. The main differential diagnosis is the Griscelli syndrome, a rare autosomal recessive disorder caused by mutations in the MYO5A or RAB27A genes. This syndrome manifests with partial albinism, silvery hair, variable neurological involvement and immunodeficiency, and progresses towards the accelerated phase as in CHS, but differs from CHS in view of the absence of giant intracytoplasmic granules in the leukocytes observed either in the peripheral blood smear or by genetic analysis.10,11

 

REFERENCES

1. Ward DM, Shiflett SL, Kaplan J. Chediak-Higashi syndrome: a clinical and molecular view of a rare lysosomal storage disorder. Curr Mol Med. 2002;2:469-77.         [ Links ]

2. Durandy A, Breton-Gorius J, Gay-Grand D, Dumez C, Griscelli C. Prenatal diagnosis of syndromes associating albinism and immune deficiencies (Chediak-Higashi syndrome and variant). Prenat Diagn. 1993;13:13-20.         [ Links ]

3. BenEzra D, Mengistu F, Cividalli G, Weizman Z, Merin S, Auerbach E. Chediak-Higashi syndrome: ocular findings. J Pediatr Ophthalmol Strabis. 1980;17:68-74.         [ Links ]

4. Baetz K, Isaaz S, Griffiths GM. Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J Immunol. 1995;154:6122-31.         [ Links ]

5. Abo T, Roder J C, Abo W, Cooper MD, Balch CM. Natural killer (HNK-1+) cells in Chediak-Higashi patients are present in normal numbers but are abnormal in function and morphology. J Clin Invest. 1982;70:193-7.         [ Links ]

6. Buchanan GR, Handin RI. Platelet function in the Chediak-Higashi syndrome. Blood. 1976;47:941-8.         [ Links ]

7. Sung JH, Meyers JP, Stadlan EM, Cowen D, Wolf A. Neuropathological changes in Chediak-Higashi disease. J Neuropathol Exp Neurol. 1969;28:86-118.         [ Links ]

8. Barbosa MD, Nguyen QA, Tchernev VT, Ashley JA, Detter JC, Blaydes SM, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature. 1996;382:262-5.         [ Links ]

9. Seixas AM, Soria-Costales TA, Jabur R, Enokihara MMSS, Michalany NS, Cestari SCP, et al. Síndrome de Chediak-Higashi: relato de caso e revisão de literatura. An Bras Dermatol. 1999;74:605-9.         [ Links ]

10. Mancini AJ, Chan LS, Paller AS. Partial albinism with immunodeficiency: Griscelli syndrome: report of a case and review of the literature. J Am Acad Dermatol. 1998;38:295-300.         [ Links ]

11. Ménasché G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, et al. Mutations in RAB27A cause Griscelli syndrome associated with hemophagocytic syndrome. Nat Genet. 2000;25:173-6.         [ Links ]

 

 

Mailing address:
Giovana Tadéia Fantinato
Hospital São Paulo
Vila Clementino
04024-900 São Paulo, SP - Brazil
E-mail: giovanafantinato@uol.com.br

Received on 04.11.2010
Approved by the Advisory Board and accepted for publication on 24.03.2011.
Conflict of interest: None
Financial funding: None

 

 

* Work undertaken at the Department of Dermatology, Escola Paulista de Medicina, Federal University of São Paulo (EPM - UNIFESP), São Paulo (SP), Brazil.